期刊文献+

新型口服抗凝药不良反应发生因素及应对策略 被引量:13

下载PDF
导出
摘要 血栓栓塞性疾病,如深静脉血栓、肺栓塞以及房颤患者卒中等,严重威胁患者的生命健康。抗凝药物的出现对防治上述一系列疾病有积极作用。维生素K拮抗剂,如华法林等,作为过去几十年临床应用最广泛的口服抗凝剂,对防治血栓栓塞性疾病有重要作用。
出处 《解放军医药杂志》 CAS 2017年第4期113-116,共4页 Medical & Pharmaceutical Journal of Chinese People’s Liberation Army
基金 河北省药学会临床药学专项科研项目(YX201505)
  • 相关文献

参考文献3

二级参考文献50

  • 1Sebastian H?rtter,Regina Sennewald,Gerhard Nehmiz,Paul Reilly.Oral bioavailability of dabigatran etexilate ( P radaxa<sup>?</sup>) after co‐medication with verapamil in healthy subjects[J].Br J Clin Pharmacol.2013(4)
  • 2Greg C. Flaker,John W. Eikelboom,Olga Shestakovska,Stuart J. Connolly,Scott Kaatz,Andrzej Budaj,Steen Husted,Salim Yusuf,Gregory Y. H. Lip,Robert G. Hart.Bleeding During Treatment With Aspirin Versus Apixaban in Patients With Atrial Fibrillation Unsuitable for Warfarin: The Apixaban Versus Acetylsalicylic Acid to Prevent Stroke in Atrial Fibrillation Patients Who Have Failed or Are Unsuitable for Vitamin k Antagonist Treatment (AVERROES) Trial[J].Stroke.2012(12)
  • 3Matthew R Wanek,Edward T Horn,Subbarao Elapavaluru,Samuel C Baroody,George Sokos.Safe Use of Hemodialysis for Dabigatran Removal Before Cardiac Surgery[J].Annals of Pharmacotherapy.2012(9)
  • 4Renato D Lopes,Sana M Al-Khatib,Lars Wallentin,Hongqiu Yang,Jack Ansell,M Cecilia Bahit,Raffaele De Caterina,Paul Dorian,J Donald Easton,Cetin Erol,Justin A Ezekowitz,Bernard J Gersh,Christopher B Granger,Stefan H Hohnloser,John Horowitz,Elaine M Hylek,John JV McMurray,Puneet Mohan,Dragos Vinereanu,John H Alexander.Efficacy and safety of apixaban compared with warfarin according to patient risk of stroke and of bleeding in atrial fibrillation: a secondary analysis of a randomised controlled trial[J].The Lancet.2012(9855)
  • 5Shawn E. Fellows,Jamie M. Rosini,James A. Curtis,Emilio G. Volz.Hemorrhagic Gastritis with Dabigatran in a Patient with Renal Insufficiency[J].Journal of Emergency Medicine.2012
  • 6Don N. Chang,William E. Dager,Andrew I. Chin.Removal of Dabigatran by Hemodialysis[J].American Journal of Kidney Diseases.2012
  • 7Rajesh Krishna,Daria Stypinski,Melissa Ali,Amit Garg,Josee Cote,Andrea Maes,Bruce DeGroot,Yang Liu,Susie Li,Sandra M. Connolly,John A. Wagner,S. Aubrey Stoch.Lack of a meaningful effect of anacetrapib on the pharmacokinetics and pharmacodynamics of warfarin in healthy subjects[J].British Journal of Clinical Pharmacology.2012(1)
  • 8Joseph A.Grillo,PingZhao,JulieBullock,Brian P.Booth,MinLu,KathyRobie‐Suh,Eva GilBerglund,K. SandyPang,AtiqurRahman,LeiZhang,Lawrence J.Lesko,Shiew‐MeiHuang.Utility of a physiologically–based pharmacokinetic (PBPK) modeling approach to quantitatively predict a complex drug–drug–disease interaction scenario for rivaroxaban during the drug review process: implications for clinical practice[J].Biopharm Drug Dispos.2012(2)
  • 9Masaki Watanabe,Fazeel M. Siddiqui,Adnan I. Qureshi.Incidence and Management of Ischemic Stroke and Intracerebral Hemorrhage in Patients on Dabigatran Etexilate Treatment[J].Neurocritical Care.2012(1)
  • 10Wei Zhou,S?nke Schwarting,Sergio Illanes,Arthur Liesz,Moritz Middelhoff,Markus Zorn,Martin Bendszus,Sabine Heiland,Joanne van Ryn,Roland Veltkamp.Hemostatic Therapy in Experimental Intracerebral Hemorrhage Associated With the Direct Thrombin Inhibitor Dabigatran[J].Stroke.2011(12)

共引文献17

同被引文献127

引证文献13

二级引证文献106

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部